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Difficulty in the swallowing of conventional tablets by geriatric and pediatric pa-
tients may lead to poor patient compliance and ineffective therapy. To overcome such
problems, a new dosage form has been introduced, known as fast-dissolving tablets. In
most cases, these tablets disintegrate or dissolve in the oral cavity without the need for
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The aim of this study was to prepare fast-dissolving tab-
lets of meloxicam after its complexation with b-cyclodex-
trin (b-CD) and to investigate the effect of using different
superdisintegrants on the disintegration and release of
meloxicam from the tablets. A complex of meloxicam
with b-CD was prepared by spray drying and then com-
pressed in the form of tablets utilizing the direct compre-
ssion technique. Three superdisintegrants were employed
at various levels – sodium starch glycolate, croscarmello-
se sodium, and crospovidone. Co-spray dried micro-cry-
stalline cellulose and mannitol (Avicel HFE-102) were used
as diluents in the tablets. Prior to compression, the pre-
-compression parameters showed satisfactory flow proper-
ties. Post-compression parameters showed that all tablet
formulations had acceptable mechanical properties. Wet-
ting and disintegration times were prolonged by increas-
ing the level of sodium starch glycolate in the tablets. This
was attributed to the formation of a viscous gel layer aro-
und the tablets by sodium starch glycolate whereas this
effect was not observed with croscarmellose sodium and
crospovidone. Dissolution studies showed fast release of
meloxicam except in tablets containing a high level of so-
dium starch glycolate. Complexation of meloxicam with
b-CD significantly improved the solubility of the drug and
improved the mechanical properties of tablets produced
by direct compression.
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water or chewing. Fast-dissolving tablets are not only suitable for people with swallow-
ing difficulties, they are also ideal for active people. This new dosage form provided the
benefits of enhanced patient compliance, rapid onset of action, and increased bioavaila-
bility. Therefore, there are a number of fast-dissolving formulations in the market now
and the technology is still improving (1).
The basic principles in the development of fast-dissolving tablets are the use of super-
disintegrants or maximization of the porous structure of tablets. Several techniques have
been applied in the development of fast-dissolving tablets, such as melt granulation (2),
phase transition process (3), sublimation (4), spray drying (5), freeze drying (6), in addi-
tion to tablet moulding and direct compression (7).
Tablets produced by freeze drying show a very porous structure, so there is quick
penetration of saliva into the pores once they are placed in the oral cavity. However, the
main disadvantages of such tablets are lack of physical resistance and limited ability to
incorporate higher amounts of the active drug, as well as a high cost of production. Di-
rect compression is assumed to be a better option for the production of fast-dissolving
tablets with satisfactory disintegration times. This is the most cost effective technology
for the production of fast-dissolving tablets because it does not require special equip-
ment with a limited number of processing steps.
Meloxicam is an enolic acid, non-steroidal anti-inflammatory drug, which is mainly
indicated for osteoarthritis and rheumatoid arthritis and is characterized by poor and
pH dependent water solubility (8). Several techniques have been used to improve the
solubility and dissolution characteristics of meloxicam, mainly by its complexation with
cyclodextrins (9, 10). Meloxicam-b-CD complex has been prepared by spray drying and
characterized according to a previously published procedure from our laboratory (9). In
particular, it has been characterized by differential scanning calorimetry. Fourier trans-
form infrared spectroscopy, X-ray diffraction and intrinsic dissolution. Thus, the present
investigation was conducted to prepare optimized fast-dissolving tablets of meloxicam
after its complexation with b-CD using various superdisintegrants and using Avicel
HFE-102 as a diluent. The novelty in this study is demonstrated in optimizing the solu-
bility of meloxicam by complexation with b-CD and then formulating it into fast-dis-
solving tablets. It is likely that a porous hydrophilic matrix will easily pick up the disinte-
grating medium, break, and dissolve quickly, resulting in fast release and rapid dissolu-
tion of the drug, and hence improved absorption and bioavailability.
EXPERIMENTAL
Materials
Meloxicam, pharmaceutical grade, was a gift from the Jordanian Pharmaceutical Ma-
nufacturing Company (JPM Co., Jordan). b-Cyclodextrin (b-CD), aspartame, magnesium
stearate, and talc were form Sigma Chemical Co. (USA), sodium starch glycolate (SSG)
(Primojel) from DMV International (The Netherlands), crospovidone (CP) from BASF che-
micals (USA), croscarmellose sodium (CCS) and Avicel HFE-102 from FMC BioPolymer
(USA). Avicel HFE-102 is a new high functionality excepient made up of co-spray dried
microcrystalline cellulose and mannitol. All reagents were of pharmaceutical grade and
were used as received.
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Methods
Preparation of meloxicam-b-CD complex. – Meloxicam-b-CD complex was prepared
using the spray drying method according to a previously published procedure from our
laboratory (9). Briefly, a solution containing equal molar amounts of meloxicam and
b-CD was prepared in 200 mL borate buffer of pH 10. Then, the drug was precipitated
by lowering the solution pH to 2.8 by adding 0.2 mol L–1 HCl in order to produce sma-
ller particles of meloxicam and thus a more soluble drug. Finally, the pH of the solution
was raised to 7.4 by adding 0.2 mol L–1 NaOH. The solution was then spray dried using
a mini spray dryer (Büchi 190 mini spray dryer, Germany). The inlet and outlet tempera-
tures were 134 and 84 °C, respectively. Characterization of the complex regarding stoi-
chiometry and stability was proved previously (9) and no further investigations were
performed on the meloxicam-b-CD complex.
Preparation of tablets. – An amount of the complex (meloxicam-b-CD) equivalent to
15 mg of meloxicam was blended with directly compressible diluents and superdisin-
tegrants in a plastic bag for 20 minutes. Magnesium stearate, aspartame and talc were
passed through a 0.25-mm sieve, mixed and then blended with the initial mixture in the
plastic bag. The blend was then compressed using a single-punch tablet press (Erweka,
Germany) and using 9-mm diameter circular punches with flat faces under compression
of 2´103 kg. Machine settings were adjusted to produce tablets having the same hard-
ness and mass. Nine formulations were prepared with a target mass of 250 mg (formula-
tions codes F1–F9). The composition of these formulations is shown in Table I. Prior to
compression, powder blends were evaluated for pre-compression parameters like Haus-
ner’s ratio [tapped/bulk density ratio using a tapped volumeter apparatus (Copley Sci-
entific, UK)], Carr’s compressibility index (11), and static angle of repose. To measure
the angle of repose, 10 mL of powder was poured through a glass funnel onto a flat sur-
face and the angle to the horizontal was measured. The measurements were performed
in triplicate.
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Table I. Composition of fast-dissolving tablets of meloxicam
Ingredient (mg)a F1 F2 F3 F4 F5 F6 F7 F8 F9
Complexb 23.8 23.8 23.8 23.8 23.8 23.8 23.8 23.8 23.8
Avicel HFE-102 214.2 209.2 204.2 214.2 209.2 204.2 214.2 209.2 204.2
SSG 5 10 15 – – – – – –
CCS – – – 5 10 15 – – –
CP – – – – – – 5 10 15
Aspartame 5 5 5 5 5 5 5 5 5
Talc 1 1 1 1 1 1 1 1 1
Mg-stearate 1 1 1 1 1 1 1 1 1
Total mass 250 250 250 250 250 250 250 250 250
a A batch of 80 tablets was prepared from each formulation.
b Amount of complex (meloxicam-b-CD) is equivalent to 15 mg of meloxicam.
Characterization of tablets. – Physical properties of the tablets were determined ac-
cording to the USP 24 methods (12). Mass variation was performed on 20 tablets selected
at random. Hardness of the tablets was measured by recording the force to fracture a
tablet on a hardness tester for 6 tablets from each formulation (Copley Scientific). Fria-
bility was determined using an Erweka friability tester for 20 tablets at 100 rpm for 4
minutes. Six tablets were tested from each formulation for disintegration time at 37 ± 0.5 °C
in water. To investigate the wetting time of the tablets, a twice folded piece of tissue pa-
per was placed in a small Petri dish containing 5 mL of distilled water. A tablet was pla-
ced on the paper and the time required for complete wetting of the tablet was recorded
in seconds. For determination of drug content, a total of 10 tablets were weighed and
powdered. A powder mass equivalent to 15 mg of meloxicam was weighed, dissolved in
methanol and filtered. The filtrate was collected, diluted suitably and analyzed for the
content of meloxicam by UV-spectroscopy at 362 nm (Cintra 5 UV-visible spectrophoto-
meter, Australia) (9).
In vitro release study. – The in vitro dissolution study was carried out according to
the USP 24 specifications (12) with Apparatus II (n = 6) using an Erweka dissolution ap-
paratus DT-D6. The dissolution medium consisted of 900 mL of pH 6.8 phosphate buffer
solution maintained at 37 ± 0.5 °C and stirred at 50 rpm. Aliquot samples (5 mL) were
withdrawn every minute, filtered through a 0.45-µm membrane filter (Millipore, USA)
and replaced by an equivalent volume of fresh dissolution medium. The samples were
suitably diluted and the amount of the drug dissolved was analyzed spectrophotometri-
cally at 362 nm.
RESULTS AND DISCUSSION
Prior to compression, the powder blends were evaluated for the most important pa-
rameters referring to flowability and compression. Table II shows the pre-compression
parameters of the powder blends used in the compression of meloxicam fast-dissolving
tablets. The blends were found to have excellent flowability as determined by Hausner’s
ratio, compressibility index and angle of repose. The compressibility index ranged from
12.3 to 15.1 %. Compressibility index values of up to 15 % generally indicate excellent
flow properties in regard to compressibility-flowability correlation data. Hausner’s ratio
was approximately higher than 1 and the angle of repose ranged from 18–21° for all the
formulation blends. Therefore, the values of pre-compression parameters were within the
prescribed limits and indicated excellent flow properties.
Avicel HFE-102 was used in the formulation of meloxicam fast-dissolving tablets un-
der study. It provides a synergistic functionality over the individual or dry blended com-
ponents (cellulose and mannitol) with better flow, compaction, and disintegration prop-
erties compared to traditional microcrystalline cellulose grades. It is intended for utiliza-
tion in direct compression of tablets and instant release oral solid dosage forms (13).
The post-compression parameters such as hardness, friability, drug content, and
tablet mass variations are presented in Table III. The hardness test indicated good me-
chanical strength with non-significant differences in all formulations. It is assumed that
the presence of b-CD in the formulation resulted in lower friability of the tablets. It has
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been shown by other investigators that the friability of tablets decreased as the concen-
tration of b-CD was increased (14). This has been attributed to the water of crystalliza-
tion present in b-CD which helps in the binding of particles and production of stronger
tablets (15). All the tablets showed good mechanical resistance, as indicated by the fria-
bility test where it was less than 1 % for all tablets. Drug content was found to be consis-
tent and almost uniform in all tablet formulations (> 98 %) and no significant statistical
mass variability was observed in the produced tablets. Therefore, our results, as indi-
cated by the post-compression parameters presented in Table III, showed that an excel-
lent degree of uniformity was achieved for all prepared tablet formulations.
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Table II. Pre-compression parameters of the powder blends used in the preparation of meloxicam
fast-dissolving tablets
Formulation Hausner’s ratioa Compressibility index (%)a Angle of repose (q, °)a
F1 1.13 ± 0.05 13.75 ± 0.11 21.35 ± 0.06
F2 1.12 ± 0.04 13.87 ± 0.18 21.86 ± 0.08
F3 1.10 ± 0.07 14.39 ± 0.16 20.55 ± 0.11
F4 1.15 ± 0.05 12.25 ± 0.18 18.28 ± 0.15
F5 1.17 ± 0.09 15.08 ± 0.13 19.15 ± 0.11
F6 1.19 ± 0.11 14.47 ± 0.91 21.45 ± 0.14
F7 1.22 ± 0.09 13.75 ± 0.16 20.85 ± 0.09
F8 1.18 ± 0.12 13.83 ± 0.15 19.74 ± 0.12
F9 1.14 ± 0.08 14.22 ± 0.12 20.39 ± 0.09
a Mean ± SD, n = 3.
Table III. Evaluation of meloxicam fast-dissolving tablets (post-compression parameters)
Formulation Hardness (kg cm–2)a,b Friability (%)a,c Drug content (%)a,d Mass (mg)a,c
F1 3.6 ± 0.1 0.56 ± 0.1 100.8 ± 1.2 250.34 ± 1.7
F2 3.4 ± 0.2 0.55 ± 0.1 98.46 ± 1.4 250.26 ± 1.1
F3 3.3 ± 0.1 0.53 ± 0.1 99.86 ± 1.2 250.15 ± 1.4
F4 3.3 ± 0.1 0.51 ± 0.2 99.80 ± 1.6 249.92 ± 1.9
F5 3.5 ± 0.2 0.48 ± 0.2 99.26 ± 1.3 249.98 ± 1.8
F6 3.7 ± 0.2 0.56 ± 0.1 99.93 ± 1.4 250.12 ± 1.9
F7 3.5 ± 0.1 0.52 ± 0.2 100.6 ± 1.3 250.45 ± 0.8
F8 3.6 ± 0.1 0.58 ± 0.2 99.66 ± 1.5 250.24 ± 1.8
F9 3.8 ± 0.2 0.53 ± 0.1 99.13 ± 1.6 250.24 ± 1.8
a Mean ± SD.
b n = 6, c n = 20, d n = 10.
The in vitro disintegration and wetting times are presented in Table IV. The in vitro
disintegration times ranged from 26 to 56 s and the wetting times varied from 38 to 82 s.
However, regarding both the wetting and the in vitro disintegration times, it was obser-
ved that such times increased by increasing the amount of SSG in the tablet formulation.
On the other hand, rapid disintegration times were obtained by increasing the level of
CCS and CP in tablet formulations where the tablets disintegrated within shorter times
compared to tablets containing SSG as a superdisintegrant. This indicated that increas-
ing the level of SSG in the tablet had a negative effect on its disintegration time. Tablets
containing SSG disintegrate due to rapid uptake of water and then rapid and enormous
swelling into primary particles. At higher SSG levels, a viscous gel layer was formed
around the tablets, which created a barrier to further penetration of the disintegration
medium into the tablet. The effect of using higher concentrations of SSG was previously
demonstrated to slow down the disintegration and drug release from tablets due to for-
mation of a viscous barrier around the tablets (16). CCS and CP provided better disinte-
gration times due to their better swelling abilities and rapid disintegration. CCS and CP
have high capillary activity and pronounced hydration but little tendency to gel forma-
tion. Therefore, rapid disintegration and, hence, rapid dissolution is expected.
Wetting time is one of the indicators of fast disintegration and dissolution of fast-
-dissolving tablets (17). Our results also showed that the wetting time decreased by in-
creasing the levels of CCS or CP in tablet formulations. However, when the level of SSG
was increased in the tablet formulation from 2 to 6 %, the wetting time increased from 58
to 82 s, respectively. These results are consistent with the disintegration times and can be
also explained by slower migration of water into the tablet due to formation of a viscous
barrier by increasing the level of SSG in tablets.
Dissolution of meloxicam is presented as cumulative percent released over time from
tablets containing SSG, CCS and CP (Fig. 1). To examine the influence of superdisinteg-
rants on the release of meloxicam from the tablets, the time for 50 % release of meloxi-
cam (t50) was taken into account. It can be noticed that t50 increased by increasing the
level of SSG in the tablets (Fig. 1a). It increased from almost 1 minute at the low level (2
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Table IV. Evaluation of wetting and disintegration times of meloxicam fast-dissolving tablets
Formulation Wetting time (s)a Disintegration time (s)a
F1 58 ± 2 36 ± 1
F2 75 ± 1 42 ± 1
F3 82 ± 2 56
F4 65 ± 1 37
F5 56 ± 1 32 ± 1
F6 52 ± 1 26 ± 1
F7 42 ± 1 35 ± 1
F8 41 ± 1 31
F9 38 ± 1 27
a Mean ± SD, n = 6.
%) to more than 4 minutes at the high level of SSG (6 %). The t50 was found to decrease
by increasing the levels of CCS and CP in the tablets (Figs. 1b and 1c, resp.). The t50 was
around 1 minute in both cases. Among all formulations studied, formulation F6 was found
best regarding drug release, for it gave 98 % release of the drug within 4 minutes. In ad-
dition, this formulation showed the shortest disintegration time of 26 s. Formulation F6
contained 6 % of CCS as superdisintegrant in addition to other basic excepients and had
a drug content of 99.9 % (Tables I and III).
CONCLUSIONS
The use of superdisintegrants for preparation of meloxicam fast-dissolving tablets
by direct compression was found highly effective in this study. Optimized fast-dissolv-
ing tablets of meloxicam were prepared after complexation of meloxicam with b-CD.
Dissolution of meloxicam from the tested formulations was fast, which can probably be
attributed to its complextaion with b-CD. Furthermore, using b-CD facilitated the phar-
maceutical preparation of the tablets. In particular, it enhances the compression behav-
89
A. A. Obaidat and R. M. Obaidat: Development and evaluation of fast-dissolving tablets of meloxicam-b-cyclodextrin complex












































































Fig. 1. Dissolution profiles of meloxicam fast-
-dissolving tablets prepared with: a) SSG, b)
CCS, and c) CP at pH 6.8 and temperature of
37 ± 0.5 °C (n = 6).
ior since it has contributed to good mechanical properties of the tablets when employed
in the direct compression technique. Based on our results, formulation F6 with 99.9 %
drug and 6 % of CCS as a superdisintegrant in addition to the other basic excipients seems
to be a formulation of choice for further in vivo testing.
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S A @ E T A K
Razvoj i vrednovanje lako topljivih tableta kompleksa meloksikama
s -ciklodekstrinom pripravljenih izravnom kompresijom
AIMAN A. OBAIDAT i RANA M. OBAIDAT
Cilj rada bio je priprava lako topljivih tableta kompleksa meloksikama s b-ciklodeks-
trinom (b-CD) te ispitati utjecaj razli~itih superdezintegratora na raspadljivost tableta i
osloba|anje meloksikama. Kompleks meloksikama s b-CD pripravljen je metodom su{e-
nja sprejem, a komprimiran je u tablete metodom izravne kompresije. U pripravi tableta
kori{tene su tri razli~ite koli~ine triju superdezintegratora: natrijev {krobni glikolat, na-
trijeva sol kroskarmeloze i krospovidon, dok su mikrokristalini~na celuloza i manitol (Avi-
cel HFE-102) upotrijebljeni kao punila. Predkompresijski parametri ukazivali su na za-
dovoljavaju}u te~nost. Postkompresijski parametri pokazali su da sve tablete imaju pri-
hvatljiva mehani~ka svojstva. Vla`enje i vrijeme raspadanja bilo je produljeno kada se
pove}ao udio natrijevog {krobnog glikolata u tabletama. To je pripisano stvaranju vis-
koznog sloja gela oko tableta, {to nije primije}eno u pripravi tableta s natrijevom soli
kroskarmeloze i krospovidonom. Osloba|anje meloksikama bilo je brzo iz svih tableta,
osim iz tableta s visokim udjelom natrijeve soli {krobnog glikolata. Kompleksiranje me-
loksikama s b-CD zna~ajno je pove}alo topljivost lijeka i pobolj{alo mehani~ka svojstva
tableta.
Klju~ne rije~i: meloksikam, natrijev {krobni glikolat, natrijeva sol kroskarmeloze, krospovidon,
b-ciklodekstrin
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